Treatment of Autoimmune Patients with CD19-CAR T Cells Results in Long-Term Drug-Free Remission or No Progression
Fabian Müller from the University Clinic of Erlangen presented updated data on the treatment of autoimmune patients with CD19-CAR T-cell therapy at ASH 2024. Data from 35 patients demonstrated a 100% remission rate at six months with a strong safety profile and deep B-cell depletion. Long-term follow-ups revealed long-term drug-free remission or no progression, with disease recurrence in only one patient